Literature DB >> 17379322

PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.

Tor Molden1, Irene Kraus, Hanne Skomedal, Trine Nordstrøm, Frank Karlsen.   

Abstract

Monitoring human papillomavirus (HPV) E6/E7 mRNA expression may provide an accurate and informative diagnostic approach for detection of oncogene activity related to the development of severe dysplasia or cervical carcinoma. A multiplex nucleic acid sequence based amplification (NASBA) assay, utilizing molecular beacon probes for real-time detection was developed for the identification of E6/E7 mRNA from HPV types 16, 18, 31, 33 and 45. The assay is called PreTect HPV-Proofer and this report describes the development and the analytical performance of the assay. The reproducibility of PreTect HPV-Proofer with regard to a positive result was found to be between 96 and 100%, depending on HPV type. The melting temperature for the different molecular beacons was in the range of 48-55 degrees C, indicating conformational stability, i.e. the molecular beacons will not get activated by the 41 degrees C annealing temperature, but will be activated by the annealing to the target itself. The limit of detection for HPV 16 was ten SiHa or CaSki cells and for HPV 18 one HeLa cell. No cross reactivity was observed with E6/E7 mRNA from the other tested HPV types. mRNA from cervical cells was also successfully amplified after more than one year of storage. In conclusion, the PreTect HPV-Proofer assay, individually identifying E6/E7 mRNA expression from five carcinogenic HPV types, is a reproducible assay that may serve as a valuable tool in monitoring HPV infections producing proteins with a transforming potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379322     DOI: 10.1016/j.jviromet.2007.01.036

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  22 in total

1.  MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer.

Authors:  Partha Basu; Puneet Chandna; R N K Bamezai; Maqsood Siddiqi; Dhananjaya Saranath; Adrian Lear; Sam Ratnam
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

Review 2.  Advances in technologies for cervical cancer detection in low-resource settings.

Authors:  Kathryn A Kundrod; Chelsey A Smith; Brady Hunt; Richard A Schwarz; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Expert Rev Mol Diagn       Date:  2019-08-01       Impact factor: 5.225

3.  Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.

Authors:  Anne Szarewski; David Mesher; Louise Cadman; Janet Austin; Lesley Ashdown-Barr; Linda Ho; George Terry; Stuart Liddle; Martin Young; Mark Stoler; Julie McCarthy; Corrina Wright; Christine Bergeron; W P Soutter; Deirdre Lyons; Jack Cuzick
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

4.  Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Authors:  Samuel Ratnam; Francois Coutlee; Dan Fontaine; James Bentley; Nicholas Escott; Prafull Ghatage; Veeresh Gadag; Glen Holloway; Elias Bartellas; Nick Kum; Christopher Giede; Adrian Lear
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

5.  Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification.

Authors:  Gaëlle A V Boulet; Isabel M Micalessi; Caroline A J Horvath; Ina H Benoy; Christophe E Depuydt; Johannes J Bogers
Journal:  J Clin Microbiol       Date:  2010-05-12       Impact factor: 5.948

6.  Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.

Authors:  Samuel Ratnam; Francois Coutlee; Dan Fontaine; James Bentley; Nicholas Escott; Prafull Ghatage; Veeresh Gadag; Glen Holloway; Elias Bartellas; Nick Kum; Christopher Giede; Adrian Lear
Journal:  J Clin Microbiol       Date:  2010-12-08       Impact factor: 5.948

7.  A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men.

Authors:  Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Lauren M Schwartz; Thomas S Lorey; Brandon LaMere; Julia C Gage; Barbara Fetterman; Teresa M Darragh; Ana Cecilia Rodriguez; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-11-15       Impact factor: 4.254

8.  HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract.

Authors:  Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Roberto Fuson; Helena Frayle-Salamanca; Rossana Trevisan; Annarosa Del Mistro
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-08       Impact factor: 4.553

9.  Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.

Authors:  Paola Cattani; Gian Franco Zannoni; Caterina Ricci; Sara D'Onghia; Ilaria Nausica Trivellizzi; Aldo Di Franco; Valerio G Vellone; Maria Durante; Giovanni Fadda; Giovanni Scambia; Giovanni Capelli; Rosa De Vincenzo
Journal:  J Clin Microbiol       Date:  2009-10-14       Impact factor: 5.948

10.  Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.

Authors:  Ruth Holm; Irene Kraus; Hanne Skomedal; Anita Langerød; Gunnar B Kristensen; Heidi Lyng
Journal:  Open Virol J       Date:  2008-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.